Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (Nasdaq: VKTX) reported Q4 and full-year 2025 results and provided a corporate update highlighting rapid clinical progress in obesity programs.
Key points: strong cash position of $706 million, VANQUISH-1 enrollment >4,500, oral VK2735 to enter Phase 3 in 3Q26, maintenance dosing study fully enrolled with data expected 3Q26, and an IND for a dual amylin/calcitonin agonist planned in 1Q26.
Viking Therapeutics (NASDAQ: VKTX) will release fourth-quarter and year-end 2025 financial results after market close on Wednesday, February 11, 2026. A conference call to discuss results and corporate updates begins at 4:30 p.m. ET the same day.
Investors can join by phone or listen via webcast at the company's Webcasts page; a telephone replay is available through February 18, 2026 and the webcast archive will remain on the site for 30 days.
Viking Therapeutics (NASDAQ: VKTX) announced publication in Obesity of Phase 2 VENTURE results for weekly subcutaneous VK2735, a dual GLP-1/GIP receptor agonist. The 13-week trial met its primary and secondary endpoints, showing mean body-weight reductions up to 14.7% from baseline with no plateau and a safety profile in which most adverse events were reported as mild or moderate. Viking is advancing VK2735 in the registrational VANQUISH Phase 3 program (78-week dosing); VANQUISH-1 has ~4,650 participants enrolled and VANQUISH-2 is enrolling ~1,100. An exploratory maintenance study (≈180 subjects) also completed enrollment.
Viking Therapeutics (NASDAQ: VKTX) announced completion of enrollment in a Phase 1 maintenance dosing study of VK2735, a dual GLP-1/GIP agonist being developed in oral and subcutaneous formulations for obesity. The randomized, double-blind, placebo-controlled study enrolled ~180 adults (BMI ≥30) who received 19 weeks of weekly VK2735 or placebo, then were randomized to maintenance regimens including monthly, every-other-week, weekly subcutaneous, daily or weekly oral dosing, or placebo through Week 31. Objectives include safety, tolerability, and pharmacokinetics; exploratory endpoints assess body-weight change from baseline and from Week 19. Viking also notes ongoing Phase 3 VANQUISH-1 (≈4,650 enrolled) and VANQUISH-2 (≈1,100 planned) studies of weekly subcutaneous VK2735 for up to 78 weeks, with results expected later in 2026.
Viking Therapeutics (NASDAQ: VKTX) announced on January 7, 2026 the appointment of Neil Aubuchon as chief commercial officer. Aubuchon brings more than two decades of global commercialization and marketing experience across Amgen, Eli Lilly and most recently as CCO at AbCellera.
The company said Aubuchon will lead commercialization strategy for VK2735, described as a potentially best-in-class GLP-1/GIP dual agonist currently in Phase 3 trials for obesity, and will support partner engagement and market preparation.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12-15, 2026. The presentation is scheduled for 2:15–2:55 p.m. PT on Monday, January 12, 2026. Dr. Lian will also participate in one-on-one meetings. A live webcast will be accessible from Viking Therapeutics' Investors & Media Webcasts page, and a replay will be posted after the conference.
Viking Therapeutics (NASDAQ: VKTX) announced on November 19, 2025 that enrollment is complete in the Phase 3 VANQUISH-1 trial of subcutaneous VK2735 ahead of schedule and above target. The randomized, double-blind, placebo-controlled trial enrolled ~4,650 adults with obesity or overweight plus comorbidity, randomized to VK2735 7.5 mg, 12.5 mg, 17.5 mg, or placebo. The study will evaluate percent change in body weight at 78 weeks as the primary endpoint and includes secondary/exploratory responder endpoints (≥5%, ≥10%, ≥15%, ≥20% weight loss) plus a 52-week extension. Viking said VANQUISH-2 (type 2 diabetes with obesity) is enrolling and expects enrollment completion in Q1 2026. Prior Phase 2 VENTURE showed up to 14.7% mean weight reduction after 13 weekly doses with generally mild-to-moderate adverse events.
Viking Therapeutics (NASDAQ: VKTX) presented exploratory Phase 2 VENTURE data for subcutaneous VK2735 at ObesityWeek 2025 showing improvements in cardiometabolic status after 13 weeks.
Key findings: 78% of VK2735-treated prediabetic patients shifted to normoglycemic vs 29% placebo (p=0.0008); 68% of patients with metabolic syndrome no longer met criteria vs 38% placebo (p=0.02). Up to 14.7% mean body-weight reduction and up to 88% achieved ≥10% weight loss; most drug-related TEAEs (92%) were mild or moderate. Viking also highlighted the Phase 3 VANQUISH-1 trial design.
Viking Therapeutics (NASDAQ: VKTX) will participate in two investor conferences in November 2025.
Stifel 2025 Healthcare Conference: management will hold a fireside chat and investor meetings on Nov 11, 2025 (4:40–5:10 p.m. ET) in New York.
Jefferies 2025 Global Healthcare Conference – London: management will deliver a corporate presentation and meet investors on Nov 19, 2025 (8:00–8:25 a.m. GMT / webcast available) in London; a live webcast and replay will be available on Viking's Investors & Media Webcasts page.
Viking Therapeutics (NASDAQ: VKTX) will present clinical data and study designs for its obesity program VK2735 at ObesityWeek® 2025 (Nov 4–7, 2025) and at AHA Scientific Sessions 2025 (Nov 7–10, 2025).
ObesityWeek highlights: an exploratory analysis from the Phase 2 VENTURE study reporting 13-week effects of weekly subcutaneous VK2735 on weight, prediabetes prevalence, and metabolic syndrome, plus the Phase 3 VANQUISH-1 study design for subcutaneous VK2735 in adults with overweight or obesity.
AHA highlights: the Phase 3 VANQUISH-2 study design in Type 2 diabetes with obesity and an analysis of cardiometabolic condition prevalence across BMI categories. Presentation dates/times and presenting authors are listed for each poster.